BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//IBSAL - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IBSAL
X-ORIGINAL-URL:https://ibsal.es/en/
X-WR-CALDESC:Events for IBSAL
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250601
DTEND;VALUE=DATE:20250701
DTSTAMP:20260804T112124Z
CREATED:20250515T080245Z
LAST-MODIFIED:20260804T112124Z
UID:24748-1748736000-1751327999@ibsal.es
SUMMARY:GILEAD. Gilead Biomedical Research Grants
DESCRIPTION:Features\nWhereas the generation of scientific knowledge in the field of the sciences of the\nHealth\, its dissemination\, and its application to healthcare practice are key to achieving\nTo promote progress and improve citizens’ living conditions\, GILEAD SCIENCES\, S.L.U. promotes the  “12th Call for Applications for Gilead Scholarships for Biomedical Research in HIV\, Hematology-Oncology\, and Medical Oncology.” \nProposals submitted under this call for proposals may only pertain to research projects conducted within the national territory and with an implementation period not exceeding 24 months. This period will begin on the date the agreement for business collaboration on activities of general interest is signed\, as referred to in the “Grant Award and Notification” section of this website. Grants awarded under this call for proposals will take the form of a monetary contribution of a variable amount that may not exceed 55\,000 euros per project\, which will include administrative management expenses.   \n  \nProjects must fall within one of the following research areas:\n\nHIV:\n\nResearch to improve knowledge and the care cascade (Care Cascade) in\ncertain subpopulations of people living with HIV: \n\nolder adults (aging among people living with HIV)\nwomen\ntransgender people\nmigrant population\nsex workers\nhomeless people.\n\n\nResearch on innovative care strategies to improve early diagnosis\nand follow-up of people living with HIV\nResearch on Improving Access to and Implementation of PrEP\n\n\n\n  \n\nHematology-Oncology: B-cell non-Hodgkin lymphomas (diffuse large B-cell lymphoma\, primary mediastinal B-cell lymphoma\, mantle cell lymphoma\, follicular lymphoma)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAutomation projects and initiatives to implement improvements to existing processes\nfor CAR-T therapy treatment.\nProjects aimed at facilitating the identification of patients who are candidates for CAR-T treatment and\nimproving coordination among different levels of care to expedite treatment with\nCAR-T therapy.\nStrategies aimed at improving comprehensive patient management programs\, a multidisciplinary “\n” approach\, referral\, and coordination of care for CAR-T therapy treatment.\nClinical projects related to the study of prognostic variables and predictive\nfactors—including imaging techniques\, laboratory tests\, and\ninnovative applications of new technologies such as artificial intelligence—associated with\nCAR-T cell therapy.\nCharacterization of mechanisms of resistance to CAR-T cell therapy.\nStudies on the economic burden of the disease and cohort follow-up of patients\ntreated with CAR-T therapy in routine clinical practice.\nPreclinical and translational studies on predictive factors and mechanisms of resistance\nto CAR-T therapy.\n\n\n\n  \n\nMedical Oncology (Solid Tumors)\n\nClinical or clinical-translational projects involving patients with solid tumors in which\ninnovative applications in oncology are developed using new technologies\, such as\nartificial intelligence\, applied to clinical or molecular data.\nClinical or clinical-translational projects on solid tumors related to the study of\n\, prognostic variables\, and predictive variables.\nCohort studies or case-control studies.\n\n\n\n  \nWays to Participate:\nResearch project proposals may be submitted in one of the following formats\noptions: \n\nSingle-center study: a project submitted by a single beneficiary applicant\nin accordance with the provisions of the Second Rule of this call for proposals\, and conducted at a single\nclinical care center. Such projects may involve subcontracting\, in which case the grant recipient must\nensure that the subcontracting is carried out in accordance\nwith applicable laws and regulations. \n\n  \n\nMulticenter study: a project submitted by a single beneficiary applicant\nin accordance with the provisions of the Second Rule of this call for proposals and carried out at several\nclinical care centers. The coordinating center must list the participating centers\nin the application. \n\n  \nRequirements:\nAll proposals submitted must fall into one of the following categories of\nresearch groups: \n\nGroups led by researchers born in 1985 or later\, with a\ntrack record of scientific output that suggests they have the potential to become\nhighly competitive groups\, which must submit proposals for\ndistinctive and innovative research initiatives that do not involve the breakup of preexisting groups.\n\n  \n\nRegular groups (led by researchers born before 1985) must\nmeet the general conditions set forth in the various sections\, without\nany other specific requirements.\n\n  \nHow to apply\nApplications to participate in this call for proposals must be submitted online through this website  www.BecasGileadInvestigacion.es. \nFor this Twelfth Call for Proposals\, all information must be submitted in English (project proposal and researchers’ CVs); therefore\, projects submitted in any language other than English will not be evaluated. \nEach principal investigator may submit only one research project proposal. A maximum of two projects may be submitted per therapeutic area and healthcare facility. A “healthcare facility” is defined as the facility to which the project’s principal investigator is affiliated.   \nAt most\, only one project may be awarded per therapeutic area and per healthcare facility to which the project’s principal investigator is affiliated. For each application\, the category of research group in which the applicant participates must be indicated (a group led by researchers born in 1985 or later\, or a group led by researchers born before 1985).  \nThe information required for an application to be evaluated is as follows: \n\nResearch Project Report in accordance with the provided template.\nAbbreviated Curriculum Vitae (CVA-ISCIII)\, automatically generated by the CVN editor (http://cvn.fecyt.es/editor) or from any institution certified under the FECYT’s CVN standard that offers the CVA-ISCIII service\, for the principal investigator and all other collaborators.\nAuthorization from the director of the healthcare facility where the “\n” Project will be carried out\, in accordance with the provided form.\nArticles of Incorporation of the applicant organization.\nPower of representation of the entity’s signatory.\nRegistration of said entity in the appropriate registry.\nCertificate of Public Benefit Status for Associations.\n\n 
URL:https://ibsal.es/en/evento/gilead-gilead-biomedical-research-grants/
CATEGORIES:Calls for research
END:VEVENT
END:VCALENDAR